|
|
|
|
||
NASH Potential Market?This is from Biopharma Dive. Whatever the real numbers are, they are huge and the payoff is enormous... "Researchers are certain a liver disease known as NASH affects a large number of people, they're just not sure how high the number goes. The National Institutes of Health has a broad guess: between 3% and 12% of U.S. adults, or roughly 10 million to 30 million people. That estimate can be traced back to two studies which, combined, looked at data from less than 400 patients. The division within NIH responsible for overseeing liver diseases doesn't have any of its own statistics on how many patients have NASH, or nonalcoholic steatohepatitis. "They're closer to astrological numbers than astronomical," Pasha Sarraf, an analyst at SVB Leerink, told BioPharma Dive in an interview, speaking generally about NASH population estimates. "They're just made up numbers," he said, "and I don't believe any of them." The NASH population's size isn't the only uncertainty. Drug companies and liver organizations have signaled that NASH medicines represent a $35 billion market opportunity." |
return to message board, top of board |